C4 Therapeutics (CCCC) Income from Non-Controlling Interests (2024 - 2026)
C4 Therapeutics' (CCCC) quarterly Income from Non-Controlling Interests came in at -$372000.0 in Q1 2026, down 3620.0% year-on-year from $10568.2 in Q1 2025, and down 417.95% quarter-over-quarter from $117000.0 in Q3 2025.
C4 Therapeutics (CCCC) Income from Non-Controlling Interests (2024 - 2026) Analysis & Trends
C4 Therapeutics' Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at -$372000.0 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | C4 Therapeutics | 460.17 Mn | 224.50 Mn | - | -372,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -372,000.00 |
| Sep 30, 2025 | 117,000.00 |
| Mar 31, 2025 | -10,000.00 |
| Sep 30, 2024 | 895,000.00 |